Aimei Health Technology Co., Ltd.(AFJK)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AFJK Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Aimei Health Technology Co., Ltd. (AFJK), a Financials sector company. AFJK is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Aimei Health Technology Co., Ltd. reports net income of $45.4K, free cash flow of $-74.6K. Top institutional holders of AFJK by reported 13-F value include First Capital Management L.P., Clear Street Group, Karpus Management,, based on the most recent SEC filings. AFJK trades on the Nasdaq exchange and files with the SEC under CIK 1979005. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AFJK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aimei Health Technology Co., Ltd. directly from SEC EDGAR.
Net Income
Q1 2026
$45.4K
Free Cash Flow
Q1 2026
$-74.6K
AI Insight: AFJK Financial Trends
Insufficient data to assess trends; revenue entirely absent, all reported figures near or at zero across eight quarters.
• Equity deteriorated from -$1M in Q2 2024 to -$4M in Q1 2026, signaling persistent balance-sheet weakness.
⚠ Revenue field is blank across all periods; unable to validate business viability or growth trajectory.
⚠ Negative equity position has doubled over 18 months, indicating structural solvency stress.
AI Insight: AFJK Ratio Trends
ROA collapsed to 1.5% in Q1 2026, the lowest in the dataset, signaling severe operational deterioration.
• ROA has declined sharply from 3.8% in Q2 2025 to 1.5% in Q1 2026, a 58% drop over nine months.
• TTM ROA stands at 7.5%, but latest quarter performance (1.5%) suggests trend is decelerating materially.
⚠ Q1 2026 ROA of 1.5% represents the lowest quarterly return on assets in the entire 18-month history.
⚠ Volatility persists: ROA ranged from 1.7% (Q1 2025) to 4.1% (Q3 2024), indicating unstable profitability.
Get alerted when AFJK's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Aimei Health Technology Co., Ltd. including:
Top Institutional Holders of AFJK
First Trust Capital Management L.P.
$7.7M680,000 shClear Street Group Inc.
$947.5K83,337 shKarpus Management, Inc.
$888.5K77,125 shHarraden Circle Investments, LLC
$307.3K997,448 shHIGHBRIDGE CAPITAL MANAGEMENT LLC
$275.0K873,044 shJPMORGAN CHASE & CO
$275.0K873,044 shTORONTO DOMINION BANK
$191.6K622,219 shClear Street Group Inc.
$120.4K390,777 shWestchester Capital Management, LLC
$92.5K288,212 shWOLVERINE ASSET MANAGEMENT LLC
$89.8K291,409 sh
| Fund | Value | Shares |
|---|---|---|
| First Trust Capital Management L.P. | $7.7M | 680,000 |
| Clear Street Group Inc. | $947.5K | 83,337 |
| Karpus Management, Inc. | $888.5K | 77,125 |
| Harraden Circle Investments, LLC | $307.3K | 997,448 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $275.0K | 873,044 |
| JPMORGAN CHASE & CO | $275.0K | 873,044 |
| TORONTO DOMINION BANK | $191.6K | 622,219 |
| Clear Street Group Inc. | $120.4K | 390,777 |
| Westchester Capital Management, LLC | $92.5K | 288,212 |
| WOLVERINE ASSET MANAGEMENT LLC | $89.8K | 291,409 |
More Financials Companies
View all Financials →Put AFJK on your watchlist
Track score changes the day Aimei Health Technology Co., Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AFJK a good stock to buy?
13F Pro's AI-powered analysis of Aimei Health Technology Co., Ltd. (AFJK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Financials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AFJK are available on the AFJK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AFJK?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AFJK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aimei Health Technology Co., Ltd.'s investment landscape.